LIST OF TABLES

Table 1.1 Categories and properties of cardiovascular risk factors

Table 2.1 Serum cardiovascular disease risk marker characteristics

Table 2.2 Gender-specific population distributions of high-sensitivity C-reactive protein

Table 2.3 Biological properties and functions of high-sensitivity C-reactive protein

Table 2.4 Major prospective studies investigating high-sensitivity C-reactive protein as a marker of future cardiovascular risk among apparently healthy individuals

Table 2.5 Major studies of the association between high-sensitivity C-reactive protein and stroke

Table 3.1 Sources of kits

Table 3.2 List of parameters in patients with cardiovascular disease

Table 3.3 List of parameters in patients with stroke

Table 4.1 Clinical characteristics of the study subjects (Cardiovascular disease)
   Table 4.1.1 Non-modifiable risk factors
   Table 4.1.2 Modifiable risk factors with treatment of study entry

Table 4.2 Baseline mean levels of the biochemical parameters examined in serum samples of all patients

Table 4.3 Percentage of high-sensitivity C-reactive protein among individuals with the metabolic syndrome, diabetes, hypertension, atherogenic dyslipidemia and cardiovascular disease

Table 4.4 Baseline mean levels of the various lipids and lipoproteins ratios

Table 4.5 Percentage of high-sensitivity C-reactive protein with lipid profile and uric acid in patients with cardiovascular disease

Table 4.6 Clinical characteristic of study patients (Stroke)

Table 4.7 Baseline mean levels of the biochemical parameters examined in serum samples of all patients

Table 4.8 Changes in mean high-sensitivity C-reactive protein levels in group II and group III
Table 4.9 Changes in mean total cholesterol and low-density lipoprotein cholesterol levels in patients after atorvastatin therapy

Table 4.10 Changes in mean total cholesterol and low-density lipoprotein cholesterol levels in untreated patients

Table 4.11 Changes in mean triglycerides levels in group II and group III

Table 4.12 Changes in mean high-density lipoprotein cholesterol levels in group II and group III

Table 4.13 Changes in mean very low-density lipoprotein cholesterol levels in group II and group III

Table 4.14 Changes in mean non-HDL cholesterol levels in group II and group III

Table 4.15 Changes in mean total cholesterol and low-density lipoprotein cholesterol levels in patients after atorvastatin therapy

Table 4.16 Changes in mean total cholesterol and low-density lipoprotein cholesterol levels in untreated patients

Table 4.17 Changes in mean high-density lipoprotein cholesterol levels in group IV and group V

Table 4.18 Changes in mean non-HDL cholesterol levels in group IV and group V

Table 4.19 Changes in mean high-sensitivity C-reactive protein levels in group IV and group V

Table 4.20 Changes in mean serum glutamic oxaloacetic transaminase levels in group I, IV and V

Table 4.21 Changes in mean serum glutamic pyruvic transaminase levels in group I, IV and V

Table 4.22 Changes in mean urea levels in group I, IV and V

Table 4.23 Changes in mean creatinine levels in group I, IV and V